ArticleTherapeutics and clinical risk management2023

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy.

Giorgio Lorenzo Colombo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.